Gilead and partner Arcellx reported pivotal‑stage CAR‑T data for anito‑cel showing deep and durable responses in multiple myeloma: tumor response in 96% of 117 patients and complete remission in 74%, with no new safety signals in the latest analysis. Gilead's Kite leadership described the data as positioning anito‑cel as a best‑in‑class candidate and signaled commercialization planning ahead of potential approvals. The results will factor heavily into competitive dynamics with existing CAR‑T products and influence payer and site‑of‑care strategies for broader CAR‑T adoption.